HMT advised Imperial Innovations, the UK’s leading technology commercialisation and investment company, on its £4 million investment in Stanmore Implants.
Stanmore Implants is a specialist in the design and manufacture of patient specific implants for complex orthopaedic reconstructions. Stamnore currently focuses on orthopaedic oncology, and complex primary and secondary revisions in the upper limb, lower limb and pelvis, with a custom design and manufacture service.
The proceeds will be used to expand Stanmore’s US and UK sales forces for its current products including the Juvenile Tumour System (“JTS”), a non-invasive extendable implant, and to support Stanmore’s development of its innovative and differentiated new technologies; the Savile Row System, the world’s first fully personalised early knee replacement surgery system, and ITAP, a novel approach enabling the direct attachment of an exoprosthesis to the skeleton of amputees.
John Holden, Investment Director of Imperial Innovations commented:
“It was a pleasure working with the team. The financial due diligence was invaluable, delivered with professionalism and addressing the commercial issues. I look forward to working with them again.”